And there's the biogenerics they are developing with TEVA, not in clinical trials yet but my guess is they are aiming to a much bigger market than the Gaucher.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.